Results for trisomy translation from English to Maltese

trisomy x
sindrome tal-x triplu

reagents for evaluating the risk of trisomy 21
reaġenti biex jevalwaw ir-riskju tat-trisomja 21

a trend towards improved pfs was observed in patients with 17p deletion, trisomy 12 and normal karyotype, which did not reach significance due to small sample size.
xejra lejn pfs imtejjeb kienet osservata f’pazjenti bi tneħħija ta’ 17q, trisomy 12 u karjotip normali, li ma laħqitx sinifikanza minħabba daqs ta’ kampjun żgħir.

in first line patients, treated with either mabcampath or chlorambucil, there were 21 patients with the 17p deletion, 54 patients with 11q deletion, 34 patients with trisomy 12, 51 patients with normal karyotype and 67 patients with sole 13q deletion.
f’pazjenti kkurati għall-ewwel darba, b’mabcampath jew b’chlorambucil, kien hemm 21 pazjent bi tneħħija ta’ bis-17 p, 54 pazjent bi tneħħija ta’ 11 q, 34 pazjent b’trisomy 12, 51 pazjent b’karjotip normali u 67 pazjent bi tneħħija ta’ 13 q waħedha.

reagents and reagent products, including related calibrators and control materials, for determining the following tumoral marker: psa, - reagents and reagent products, including related calibrators, control materials and software, designed specifically for evaluating the risk of trisomy 21,
reaġenti u prodotti reaġenti, inklużi l-kalibraturi u l-materjali tal-kontroll li għandhom x'jaqsmu magħhom, biex jistabbilixxu l-markatur tumorali: il-psa, - reaġenti u prodotti reaġenti, inklużi l-kalibraturi, il-materjali tal-kontroll u s-software li għandhom x'jaqsmu magħhom, ddisinjati speċifiament biex jevalwaw ir-riskju tat-trisomja 21,